Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer von Park, Se Hoon, Breitbach, Caroline J, Lee, Jeeyun, Park, Joon Oh, Lim, Ho Yeong, Kang, Won Ki, Moon, Anne, Mun, Jae-Hee, Sommermann, Erica M, Maruri Avidal, Liliana, Patt, Rick, Pelusio, Adina, Burke, James, Hwang, Tae-Ho, Kirn, David, Park, Young Suk

Volltext

Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients von Cripe, Timothy P, Ngo, Minhtran C, Geller, James I, Louis, Chrystal U, Currier, Mark A, Racadio, John M, Towbin, Alexander J, Rooney, Cliona M, Pelusio, Adina, Moon, Anne, Hwang, Tae-Ho, Burke, James M, Bell, John C, Kirn, David H, Breitbach, Caroline J

Volltext

PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma von Abou-Alfa, Ghassan K., Galle, Peter R., Chao, Yee, Erinjeri, Joseph, Heo, Jeong, Borad, Mitesh J., Luca, Angelo, Burke, James, Pelusio, Adina, Agathon, Delphine, Lusky, Monika, Breitbach, Caroline, Qin, Shukui, Gane, Edward

Volltext

Phase II trial of pexa-vec ( pexastimogene devacirepvec ; JX-594), an oncolytic and immunotherapeutic vaccinia virus, in patients with metastatic, refractory renal cell carcinoma (... von Kim, Seong-Geun, Ha, Hong Koo, Lim, Sung-nam, De Silva, Naomi S., Pelusio, Adina, Mun, Jae Hee, Patt, Richard H., Breitbach, Caroline J., Burke, James M.

Volltext

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans von Breitbach, Caroline J., Burke, James, Jonker, Derek, Stephenson, Joe, Haas, Andrew R., Chow, Laura Q. M., Nieva, Jorge, Hwang, Tae-Ho, Moon, Anne, Patt, Richard, Pelusio, Adina, Le Boeuf, Fabrice, Burns, Joe, Evgin, Laura, De Silva, Naomi, Cvancic, Sara, Robertson, Terri, Je, Ji-Eun, Lee, Yeon-Sook, Parato, Kelley, Diallo, Jean-Simon, Fenster, Aaron, Daneshmand, Manijeh, Bell, John C., Kirn, David H.

Volltext

PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vec followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma... von Abou-Alfa, Ghassan K., Galle, Peter R., Chao, Yee, Brown, Karen T., Heo, Jeong, Borad, Mitesh J., Luca, Angelo, Pelusio, Adina, Agathon, Delphine, Lusky, Monika, Breitbach, Caroline, Burke, James, Qin, Shukui

Volltext

Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in pa... von Lee, Jeeyun, Park, Young Suk, Burke, James, Lim, Ho Yeong, Lee, Jihye, Kang, Won Ki, Park, Joon Oh, Pelusio, Adina, Breitbach, Caroline, Kirn, David H.

Volltext

A phase Ib dose escalation study of JX-594 (TK-vaccinia virus expressing GM-CSF) administered by biweekly intravenous infusion in patients with metastatic, refractory colorectal ca... von Park, Young Suk, Lee, Jeeyun, Lim, Ho Yeong, Lee, Jihye, Pelusio, Adina, Burke, James M., Breitbach, Caroline, Kirn, David H.

Volltext